CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
REVENUES:
TOTAL REVENUES	$ 6,462,110	$ 5,111,172	$ 15,186,469	$ 11,970,755
COSTS AND EXPENSES:
Cost of product sales	4,039,696	5,670,737	7,588,137	10,045,179
Research and development expenses	2,796,981	1,922,306	5,660,319	3,881,159
Selling, general and administrative expenses	6,001,353	4,397,593	12,086,422	8,554,234
Asset impairment, restructuring, severance and related costs	1,961,156	387,540	2,044,243	1,110,658
Acquisition costs	0	0	0	63,497
TOTAL COSTS AND EXPENSES	14,799,186	12,378,176	27,379,121	23,654,727
LOSS FROM OPERATIONS	(8,337,076)	(7,267,004)	(12,192,652)	(11,683,972)
OTHER EXPENSE:
Interest expense, net	(727,374)	(712,052)	(1,439,851)	(1,374,192)
LOSS BEFORE INCOME TAXES	(9,064,450)	(7,979,056)	(13,632,503)	(13,058,164)
Income tax benefit	65	135,259	67,955	214,818
NET LOSS	$ (9,064,385)	$ (7,843,797)	$ (13,564,548)	$ (12,843,346)
Basic loss per share (in dollars per share)	$ (0.45)	$ (0.42)	$ (0.67)	$ (0.71)
Diluted loss per share (in dollars per share)	$ (0.45)	$ (0.42)	$ (0.67)	$ (0.71)
Weighted average number of shares outstanding, basic (in shares)	20,219,617	18,868,144	20,191,657	18,032,723
Weighted average number of shares outstanding, diluted (in shares)	20,219,617	18,868,144	20,191,657	18,032,723
Net Product Sales [Member]
REVENUES:
TOTAL REVENUES	$ 3,931,383	$ 3,791,574	$ 7,956,045	$ 9,508,166
R&D Revenue [Member]
REVENUES:
TOTAL REVENUES	727	1,193,973	1,107,366	2,101,660
Government Grant Income [Member]
REVENUES:
TOTAL REVENUES	2,280,000	0	5,630,000	0
License and Royalty Revenue [Member]
REVENUES:
TOTAL REVENUES	$ 250,000	$ 125,625	$ 493,058	$ 360,929